Test drug APG-157 for abnormal mouth tissue
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 2 trial studies whether APG-157 can safely improve abnormal cells in the mouth (dysplasia) or early cancer-like changes (carcinoma in situ). You may be eligible if you have a visible, biopsy-proven lesion and can take oral medication while meeting blood and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (over 18) with a visible abnormal mouth or throat lesion and a biopsy showing moderate-to-severe dysplasia or carcinoma in situ
- Have a lesion big enough to measure (at least 8 mm by 3 mm before the biopsy)
- Be willing to provide blood samples, an oral rinse, and tissue from required diagnostic biopsies
- Have blood-test results that are high enough for safety (white blood cells, neutrophils, and platelets) and liver tests within allowed limits
- Not be pregnant and agree to use effective birth control during the study (or be post-menopausal or have a vasectomy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called APG-157 in people with advanced head and neck cancers of the mouth or throat. It is designed for those who are not eligible for certain standard treatments or who can have surgery or chemoradiation.
This early trial studies how safe and tolerable APG-2575 is, and how the drug moves through the body, in adults with certain relapsed or hard-to-treat blood cancers. It may help researchers learn whether the treatment could work better for people who have limited options.
This trial studies whether a two-medicine diabetes drug combination can reduce or control risky early changes in certain mouth and throat lesions. You may be asked for small tissue samples (biopsies) before and after 12 weeks to see how the lesions respond.
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
This study tests a new drug called CAN1012 to treat oral epithelial dysplasia, which are pre-cancerous changes in the mouth lining. The goal is to see if this drug can help prevent these changes from becoming cancer.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
Hear when a new Oropharyngeal Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.